This study presents a #biocompatible platform for #StemCell tracking integrating metabolic #Glycoengineering, #Bioorthogonal Chemistry & nanostar enhanced #PhotoacousticImaging enabling precise assessment of #CellTherapies.
#OpenAccess bio-integration.org/photoacousti...

DPICT is HESI Global’s open database of peer-reviewed clinical in vivo cell-tracking studies of cell therapy products to assess biodistribution and cell fate.

Explore & Submit your studies: https://dpict-celltracking.org/

#HESIGlobal #CellTherapies #Safety #Tracking #Collaboration

Gilead buys cell therapy partner Arcellx for up to $7.8bn Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

#Gilead #celltherapy #Arcellx #GileadSciences #celltherapies #cancer #oncology #CARTtherapy #multiplemyeloma #Anitocel #CARexpression #BCMAtarget #BCMAdirectedCARTs #relapsedmultiplemyeloma #refractorymultiplemyeloma #iMMagine1study #multiplemyelomapatients #BCMAbindertechnology
zurl.co/iWAbv

Gilead buys cell therapy partner Arcellx for up to $7.8bn Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

#GileadSciences has shored up its position in #celltherapies for #cancer with a deal to acquire #Arcellx, a company it has been working with since 2022, taking full control of a CAR-T therapy for #multiplemyeloma already filed for FDA approval.

pharmaphorum.com/news/gilead-...

ErVimmune raises 17m euros in funding to develop cancer vaccine - PharmaTimes The vaccine could be created as a ready-to-use product, rather than needing to be personalised

#vaccinedevelopment #ErVimmune #biotech #cancervaccine #readytousevaccine #personalisedvaccines #celltherapies #cancervaccines #cancervaccinecandidate #ErVac01 #immunotherapies #coldtumours #triplenegativebreastcancer #ovariancancer #offtheshelfcancervaccine #difficulttotreatcancers
zurl.co/Z94ou

👉 CAR‑T & TIL therapies are reshaping oncology — but their toxicities bring new challenges. Join our #ESMOOnAir webinar to learn practical strategies to recognise & manage them

🔗 Register: https://ow.ly/nP0x50XZYwC

#ESMOWebinar #celltherapies

@cgtcatapult.bsky.social has announced a new consortium to demonstrate how safety tests that detect potentially dangerous undifferentiated residual cells could be applied to a range of a #CellTherapies 🧪

Learn more ➡️ https://loom.ly/dAewfh4

What is the timeline for cell therapies?

By. Dr. @amarkelkar

#BloodCancersOncTalk2025 #BloodCancer #CancerGRACE #CancerEducation #CellTherapies

Now presenting Dr. @amarkelkar: "The Future of Medicine is Now: Emerging Cell Therapies"

#BloodCancersOncTalk #CellTherapies #CarTCell #BloodCancerEducation

GeneNovate is the first nationwide entrepreneurship program in Germany, designed to empower innovators/ entrepreneurs in the field of Gene and #CellTherapies, #Biotech, Medicine Health and Life Science.
The #GeneNovate program runs from 12/25 to 06/26.
www.nationale-strategie-gct.de/genenovate/c...

The BioHub - The Avetix Podcast - S2 Ep71 - Nick Manusos - CEO of Kenai Therapeutics Welcome back to another episode of The BioHub, we were delighted to welcome on Nick Manusos, the CEO of Kenai Therapeutics, a pioneering biotech company developing neuron replacement therapies for neurological disorders. Nick’s journey spans decades of innovation and leadership—from senior roles at global pharma giants like Baxter, Takeda, and Abbott, to founding and leading cutting-edge startups like Iota Biosciences and Opsis Therapeutics. Under his guidance, Kenai Therapeutics has secured groundbreaking funding and is advancing life-changing therapies for patients with Parkinson’s disease. He holds an MBA from Northwestern University’s Kellogg School of Management and a BBA from the University of Wisconsin, bringing a rare combination of business acumen and scientific vision to the table. Nick joins us today to share his insights on pioneering stem cell therapies, building biotech startups from the ground up, and what it takes to turn cutting-edge science into real-world solutions.

Kenai Therapeutics is on a mission to cure neurological conditions like #Parkinsons using #celltherapies. Nick Manusos, CEO of Kenai, joined The Bio Hub to share his path to Kenai, and the lessons he learned along the way. #SaiseiPortCo @kenaitx.bsky.social

Listen here: bit.ly/42aLMSY

NU25 - Day 2
'Cord blood derived cell therapies for preterm brain injury'

Professor @atulmalhotra.bsky.social Monash Children's Hospital and @monashuniversity.bsky.social

Register today bit.ly/NeonatalUpda...

@ebneo.bsky.social @espr-esn.bsky.social
#neonataology #CellTherapies #NeuroScience

Erster Spatenstich des BC GCT (v.l.): Dr. Marion Hitchcock, Managing Director of the Gene & Cell Therapies Incubator Berlin und R&D Strategy & Portfolio Manager bei Bayer; Dr. Henry Marx, Staatssekretär für Wissenschaft und Forschung des Landes Berlin; Vincent Wege, Managing Director von iQ spaces; Astrid Lurati, Vorstand Finanzen und Infrastruktur der Charité; Kai Wegner, Regierender Bürgermeister von Berlin; Prof. Heyo K. Kroemer, Vorstandsvorsitzender der Charité; Lars Klingbeil, Bundesminister der Finanzen; Stefan Oelrich, Mitglied im Vorstand der Bayer AG und Leiter der Division Pharmaceuticals; Dorothee Bär, Bundesministerin für Forschung, Technologie und Raumfahrt; Prof. Christopher Baum, Direktoriumsvorsitzender des Berlin Institute of Health in der Charité (BIH) und Vorstand Translationsforschungsbereich der Charité; Dr. Alfred Merz, Chief Executive Officer von ProBioGen; Dr. Doris Meder, Administrative Direktorin des BIH; Dr. Ruth Shah, Strategic Program Lead Gene Editing, Bayer, und Speaker Head des Co.Lab Berlin © Bayer & Charité | Norbert Ittermann

Heute feierten wir gemeinsam mit der #Charité, der #Bayer AG & der Politik den Spatenstich für das Berlin Center for #Gene and #CellTherapies (BCGCT). Es wird #Forschung, Entwicklung & Produktion vereinen & die Entwicklung von neuartigen Arzneimitteln beschleunigen. www.bihealth.org/de/aktuell/m...

Learn more about our exciting collaboration with Plurify to develop technology that improves the purity of #CellTherapies - making them safer, more efficacious and less costly to produce 👇

Due aziende biotech uniscono le forze per portare terapie innovative ai pazienti affetti da epidermolisi bollosa e ulcere venose croniche.

𝐓𝐮𝐭𝐭𝐞 𝐥𝐞 𝐢𝐧𝐟𝐨:
👉 www.osservatorioterapieavanzate.it/terapie-avan...

#celltherapies #Epidermolysisbullosa

🚀 Kick-off: Thymus-on-Chip #EUROSTARS Project!
Together with Genewity B.V. & PyroScience GmbH, we’re developing the world’s first #Thymus-on-chip platform — paving the way for more effective #CellTherapies, #DrugTesting, & #BiomedicalResearch!💉💊 Excited to push boundaries with this fantastic team! 🚀

Shooting for immune While it is still early days for CGTs in autoimmune disease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only co...

While it is still early days for CGTs in #autoimmunedisease, the field is actively pushing its own limits, working to translate scientific excitement into better, more accessible products. Not only could this lift #celltherapies to new heights, but it could redefine them entirely. 🧪🧬⑂ #SciComm

#myelomonline #multiplesmyelom #immuntherapie #forschung2025 #cartzell… | Myelom.Online e.V. 🧬 Rückblick auf den IMS-Workshop 2025 in Boston 🇺🇸 Neue Entwicklungen in der Immuntherapie beim Multiplen Myelom Vom 28.–29. März fand in Boston der internationale Workshop „Immune Effector Cell Ther...

🧬 Bilan de l’atelier #IMS 2025 à #Boston
Nouveaux développements dans le domaine de l’ #ImmunoThérapie du #MyélomeMultiple

Les 28 et 29 mars s’est tenu à Boston « l'Immune Effector #CellTherapies in Multiple #Myeloma » de l’International Myeloma Society.
#CAR-Tcells
www.ukw.de/aktuelle-mel...

Why test #celltherapies one-by-one when you can use multiplexed #SynBio #proteinengineering & #ML to design, measure & track them at scale?

The Goodman Lab @upenn.edu opens July 2025. We’re hiring at all levels!

More info: www.goodman-lab.org
Apply @ bit.ly/42BnJNJ
Reposts appreciated! 🙏

Immune Niches in Cancer & Inflammation 7-9 May 2025, Bruges, Belgium Organized in partnership with Cell Press

Join us in Bruges at the #INCI25 to discuss more about novel #celltherapies to treat #cancer

Last chance to register!
🔗 vibbio.tech/INCI25

(2/2) This work emphasizes the need to better understand genetic variants in human pluripotent #StemCells, which play a crucial role in the advancement of #CellTherapies.

Congrats to the authors, including SCN’s Vice-President, Research & Training, Jon Draper, on this significant publication! 👏

Unifying observational research with a next-generation virtual approach Explore the unification of observational research with a next-generation virtual approach in decentralised clinical trials (DCTs). Learn more about the benefits and advancements in this innovative met...

#Observationalstudies #interventionaltrials #celltherapies #genetherapies #AI #clinicaltrials #integratedendtoendtrials #DCTmodels #interventionaltrialdesigns #digitaltechnologies #patientparticipation #virtualobservationalstudies #hybridobservationalstudies
pharmaphorum.com/patients/uni...

#PortfolioNewsI We're proud to share that we've joined the oversubscribed $102M financing of our #portfolio company #NeuronaTherapeutics

🎯 Advancing regenerative #celltherapies for drug-resistant #epilepsy and severe #neurological disorders

👉 buff.ly/YHqiseP

#vc #CNS

At our free #webinar on March 20th from 12-1pm ET, LyGenesis co-Founder and CEO Michael Hufford, PhD, will discuss how his company is supporting #longevity through #Celltherapies for #organregeneration and #transplant.
Learn more & RSVP here: bit.ly/41l5slH

Cell and Gene Therapy 2025 This event will focus on the latest progress in precision genome editing, novel delivery vectors, allogeneic cell therapies and the journey from laboratory research to clinical application, offering i...

Cell and Gene Therapy 2025, hosted by Technology Networks and sponsored by Sino Biological, is happening online on March 19-20. Explore the latest in #GenomeEditing, novel delivery vectors, and allogeneic #CellTherapies. Free registration!

🔗 ow.ly/Wa2450V7cPY

Bringing new therapy to patients needs strong clinical trials and regulatory alignment. Europe is updating GCP guidelines (ICH E6(R3)) to boost efficiency while ensuring safety and transparency
💡 Why does it matter?
To deliver innovative therapies faster.
#CellTherapies #Diabetes #GCP #ACTEUworkshop

Companies To Watch: Senti Bio <p>Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of identifying cancer targets on both healthy and diseased cells.</p>

Our CEO, Tim Lu, MD, PhD, spoke with @benmcomer.bsky.social at Life Science Leader to share insights on how we plan to improve #celltherapies in oncology utilizing our logic gating technology to pinpoint diseased cells and spare healthy ones. Thanks so much for including us! #SNTI bit.ly/3Et3zM4

Thank you. From both sides. #magsep #celltherapies #leukemia #surviorship 🧡💚

CTMC's 2025 Cell Therapy Manufacturing Outlook <p>CEO Jason Bock looks back on milestones of 2024, namely an approved TIL for melanoma, and explains how it sets the stage for this year.</p>

Really good interview on the future of #celltherapies as we step into 2025. Jason Bock, CEO of CTMC, emphasized how the manufacturing platform is proportionately more important for cell therapies than with other therapies.

www.cellandgene.com/doc/ctmc-s-c...

Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity, with substantial morbidity and mortality, despite conventional immunosuppression (IS) or targeted disease modifying therapies (DMTs), which usually require repeated administration. Recently, novel cellular therapies (CT), including mesenchymal stromal cells (MSC), Chimeric Antigen Receptors T cells (CART) and regulatory T cells (Tregs), have been successfully adopted in ADs. An international expert panel of the European Society for Blood and Marrow Transplantation and the International Society for the Cell and Gene Therapy, reviewed all available evidence, based on the current literature and expert practices, on use of MSC, CART and Tregs, in AD patients with rheumatological, neurological, and gastroenterological indications.

🌟 EBMT recommendations on #AutoimmuneDiseases undergoing innovative #celltherapies #CART in @eClinicalMed. Thanks again to all the experts who contributed!

www.thelancet.com/journals/ecl...